TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03744663

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suboxone® SL
Description: Subjects will be started and titrated to optimal Suboxone® SL dose for 14 days. After the 14 day induction phase, the subject will be started on the treatment to which they were randomized to two groups one of which will be Suboxone® SL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublocade®
Description: Subjects will be started and titrated to optimal Suboxone® SL dose for 14 days. After the 14 day induction phase, the subject will be started on the treatment to which they were randomized, either Suboxone® SL or Sublocade®. Subjects with significant opioid craving (\> 20 mm on the Opioid Craving Visual Analog Scale) or withdrawal (a score of \> 12 on the Clinical Opiate Withdrawal Scale) after 14 days of treatment will be started on Sublocade® only at the consensus of the research team. Otherwise they will undergo an additional 7 day titration period. Study drug with Sublocade® group: Patients assigned to this group will receive the study drug (300 mg subcutaneously) every 4 weeks for a total of 6 doses along with weekly therapy. The location and specifications of its application will follow the recommendations by the FDA previously published.
Study: NCT06314880

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Meningococcal Group B Vaccine (E. Coli) (low-dose)
Description: Each dose contains 60μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Meningococcal Group B Vaccine (E. Coli) (low-dose)
Description: Each dose contains 60μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Meningococcal Group B Vaccine (E. Coli) (low-dose)
Description: Each dose contains 60μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Meningococcal Group B Vaccine (E. Coli) (low-dose)
Description: Each dose contains 60μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Meningococcal Group B Vaccine (E. Coli) (low-dose)
Description: Each dose contains 60μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Meningococcal Group B Vaccine (E. Coli) (hign-dose)
Description: Each dose contains 100μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Meningococcal Group B Vaccine (E. Coli) (hign-dose)
Description: Each dose contains 100μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group.
Study: NCT04725019

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active transcranial direct current stimulation
Description: Participants will receive 20 min of tDCS over the scalp during 20 min of motor training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor training
Description: Participants will engage in a high number of repetition of movements that use both hands while playing with toys and games. Training will be provided 20 min/day, for 5 consecutive days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor training
Description: Participants will engage in a high number of repetition of movements that use both hands while playing with toys and games. Training will be provided 20 min/day, for 5 consecutive days.
Study: NCT06261008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TI group
Description: CRC screening is arranged by referring the participants to the government-subsidized population-based CRC screening program. Our center is a PCP clinic offering FIT screenings under the Program. Colonoscopy is arranged if the FIT result is positive. Participants are instructed to repeat FIT at any PCP clinic 2 years after receiving a negative result. Based on the 34% local FIT screening adherence rate under SC and the assumption of improved FIT adherence to 49% after interactive TI, a minimum sample size of 332 subjects (166 per group) is required to achieve a statistical significance of p\<0.05 and power of 80%. Assuming that 10% of the subjects will drop out, be lost to follow-up, or have incomplete chatbot conversations, the required sample size is rounded up to 370 (185 per group)
Study: NCT05653804

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tele-visit
Description: The remote visit content for CPAP follow up is based on home visit framework and carried out from a secure platform for sharing health data.
Study: NCT06283277

Intervention type: DEVICE
Intervention: Obstetric Ultrasound
Description: Measuring fetal clavicular length and estimated fetal weight using Hadlock IV formula and Youssef's formula.
Study: NCT05325762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: At 21:00 on the night of tracheal extubation, propofol was administered intravenously with a microinjection pump for 2min. MOAAS/S was used to evaluate subjects 30 seconds after the end of administration.
Study: NCT05976932

Intervention type: DRUG
Intervention: pegylated liposomal doxorubicin
Description: All eligible subjects will receive the standard chemotherapy of pegylated liposomal doxorubicin monotherapy.
Study: NCT05325762

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine was at 21 PM on the day of tracheal extubation: Dexmedetomidine was injected intravenously beginning at 00. During administration, patients were evaluated with MOAA/S every 2min.
Study: NCT05564442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20% benzocaine gel
Description: compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electric nerve stimuli
Description: compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emla gel
Description: compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ice application
Description: compare the efficacy of various pain alleviating methods by application of Emla gel, TENS, and topical cooling of injection sites with 20% benzocaine gel in children 6-10 years requiring anesthesia during routine dental procedures.
Study: NCT06120309

Intervention type: DIAGNOSTIC_TEST
Intervention: CRS scoring
Description: For pathological evaluation, the omental specimens resected during the IDS were stained with haematoxylin and eosin (H\&E) and reviewed independently by two gynecologic pathologists, both blinded to the clinical data and each other's results. The pathology slide obtained from omentum, usually the site with the most viable tumor, was selected for CRS assessment according to the three-tiered CRS system recommended by 2019 ESMO ovarian cancer guidelines

Intervention type: DIAGNOSTIC_TEST
Intervention: Routine blood laboratory testing before treatment
Description: The routine blood tests and tumor marker measurements, including CA125, HE4, and inflammation-related serum biomarkers including neutrophils, lymphocytes, monocytes, fibrinogen, and platelets, were conducted within three days before the first NACT.
Study: NCT04746209

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha/Beta T-cell and B-cell depleted HCT
Description: Device: Alpha/Beta T-cell and B-cell depletion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha/Beta T-cell and B-cell depleted HCT
Description: Device: Alpha/Beta T-cell and B-cell depletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: 28 day continuous infusion given on Day 100 post-HCT if no significant ongoing GVHD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: 28 day continuous infusion given on Day 100 post-HCT if no significant ongoing GVHD
Study: NCT06453772

Intervention type: PROCEDURE
Intervention: Liposuction
Description: Primary or secondary liposuction is performed by the surgical staff. The study analyzed variables including weight, height, BMI, preoperative hemoglobin, and aspirated volume. Additionally, preoperative hemoglobin (Hb), hematocrit (Hto), platelets, prothrombin time (Tp), partial prothrombin time (TpT), and International Normalized Ratio (INR) were evaluated. Hb and Hto levels were reassessed 24 hours post-surgery to monitor changes.
Study: NCT06314880

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Meningococcal Group B Vaccine (E. Coli) (hign-dose)
Description: Each dose contains 100μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Meningococcal Group B Vaccine (E. Coli) (hign-dose)
Description: Each dose contains 100μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Meningococcal Group B Vaccine (E. Coli) (hign-dose)
Description: Each dose contains 100μg of MenB-fHBP-A and MenB-fHBP-B respectively. Administer one dose of 0.5mL each time. 20 people/group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo control
Description: Placebo control. 20 people/group.
Study: NCT05325762

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: At 21:00 PM on the day of tracheal extubation, normal saline was injected intravenously. During the administration, patients were evaluated with MOAA/S every 2 minutes.
Study: NCT05115565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS (Transcutaneous Electrical Nerve Stimulation) Application
Description: Conventional (traditional) TENS will be applied to the patients. The frequency will be 100 Hz, the pulse width (time) will be 150 μs, the current intensity (amplitude) will be 30 mA. In addition to routine care and treatment, TENS will be applied to intervention group patients.
Study: NCT04888806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: d1，200mg, iv, q3w

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ablation
Description: the 37 enrolled patients received ablation of liver/lung metastases ，If the patient has multiple metastatic tumors, ablation therapy needs to be performed in multiple times.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: standard treatment plan for mCRC, determined by the investigator
Study: NCT05874830

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbiota transplant or plasebo through endoscopy
Description: Colonoscopy and gastroscopy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fecal microbiota transplant or plasebo through endoscopy
Description: Colonoscopy and gastroscopy
Study: NCT06170567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The effect of puzzles on students' course success
Description: The effect of puzzles on students' course success

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The effect of puzzles on students' course success
Description: The effect of puzzles on students' course success
Study: NCT04884763

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments
Description: Erenumab-aooe (EREN) 140 mg s.c. administered at baseline and weeks 4, 8, 12 and 16 for a total of five treatments

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (EREN-P) s.c. administered every four weeks for a total of five treatments
Description: Placebo (EREN-P) s.c. administered at baseline and weeks 4, 8, 12 and 16 for a total of five treatments
Study: NCT05546359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride Injection
Description: Dose finding treatment for continuation to phase 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride Injection
Description: Dose finding treatment for continuation to phase 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Standard of care treatment
Study: NCT05533333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Falls prevention exercises
Description: A dual-task activity involves the simultaneous performance of two activities involving physical and cognitive tasks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Falls prevention exercises
Description: A dual-task activity involves the simultaneous performance of two activities involving physical and cognitive tasks.
Study: NCT06314880

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo control
Description: Placebo control. 20 people/group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo control
Description: Placebo control. 20 people/group.
Study: NCT05178888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRTX849
Description: KRAS G12C inhibitor
Study: NCT05194878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapyI
Description: mFOLFOXIRI (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV Irinotecan 150 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 48h every 14 days) for 6 cycles followed by colectomy (3 to 6 weeks after) . If PD was observed after 3 cycles, direct colectomy was performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colectomy
Description: Radical colectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colectomy
Description: Radical colectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant chemotherapy
Description: mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) . CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) . Oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days. The plan and cycles are determined according to the surgical pathology and physical conditions.
Study: NCT06007131

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioPumlonary Management System
Description: The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG, heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
Study: NCT05256134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: Gantenerumab will be administered as per the dosing schedule described in the Arm description.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as per the dosing schedule described in the Arm description.
Study: NCT06166238

Intervention type: PROCEDURE
Intervention: Millard and Tension Randal Technique
Description: Millard recognized that the majority of Cupid's bow, one philtral column, and the philtral dimple were intact on the medial aspect of a unilateral cleft lip but required rotation to shift the tissue into a normal anatomic position (Millard, 1964b) The Tennison-Randall technique involves a back-cut that extends from the cleft Cupid's bow peak toward the center of the philtrum that is filled by a laterally based triangular flap whose width is the measured deficiency in lip height.

Intervention type: PROCEDURE
Intervention: Millard and Tension Randal Technique
Description: Millard recognized that the majority of Cupid's bow, one philtral column, and the philtral dimple were intact on the medial aspect of a unilateral cleft lip but required rotation to shift the tissue into a normal anatomic position (Millard, 1964b) The Tennison-Randall technique involves a back-cut that extends from the cleft Cupid's bow peak toward the center of the philtrum that is filled by a laterally based triangular flap whose width is the measured deficiency in lip height.
Study: NCT06476366

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: azathioprine will be started at 0.3mg/kg. Anticipated response is after atleast 1 month so testing will be done thereafter ( after checking initial safety profile)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate will be started at 10mg/week and
Study: NCT06217484

Intervention type: BEHAVIORAL
Intervention: delayed feedback
Description: participants learn through either immediate or delayed feedback during a computer task
Study: NCT06438536

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality-based Social Cognitive Training
Description: Virtual reality assisted social cognitive training embedded in cognitive behavioral therapy, that aims at enhancing social cognition and daily life functioning.
Study: NCT05152251

Intervention type: OTHER
Intervention: Evaluation
Description: Individuals' activity participation levels and the restrictive or supportive factors affecting their participation levels and their effects on quality of life will be evaluated.

Intervention type: OTHER
Intervention: Evaluation
Description: Individuals' activity participation levels and the restrictive or supportive factors affecting their participation levels and their effects on quality of life will be evaluated.
Study: NCT06139809

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intubation
Description: Intubation will take place according to our local standard protocol for nasal intubation using NIPPV delivered through a nasopharyngeal tube. The intubation will be video-recorded to provide a clear view of the procedure and the pulse oximeter displaying the SpO2 and HR.
Study: NCT06440603

Intervention type: DIAGNOSTIC_TEST
Intervention: PCR
Description: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) for detection of EKLF:~* The method of total RNA extraction: TRIZOL and TRIZOL LS.~* The purity and concentration of the RNA will be measured using Nano Drop 2000 instument.~* cDNA will be done with primers using thr Goscript Reverse Transcription System

Intervention type: DIAGNOSTIC_TEST
Intervention: PCR
Description: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) for detection of EKLF:~* The method of total RNA extraction: TRIZOL and TRIZOL LS.~* The purity and concentration of the RNA will be measured using Nano Drop 2000 instument.~* cDNA will be done with primers using thr Goscript Reverse Transcription System

Intervention type: DIAGNOSTIC_TEST
Intervention: PCR
Description: Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) for detection of EKLF:~* The method of total RNA extraction: TRIZOL and TRIZOL LS.~* The purity and concentration of the RNA will be measured using Nano Drop 2000 instument.~* cDNA will be done with primers using thr Goscript Reverse Transcription System
Study: NCT05842486

Intervention type: OTHER
Intervention: Anti-C5 antibody treatment
Description: Anti-C5 antibody treatment (i.e., eculizumab and ravulizumab)
Study: NCT05945498

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TB/Flu-05E vaccine
Description: Participants will receive single intranasal injection of A/H1N1pdm09 recombinant attenuated influenza vector (7.7 lg EID50) with modified NS gene coding for the TB10.4 and HspX antigens of M. tuberculosis

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive single intranasal injection of placebo buffer solution
Study: NCT05508646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy intervention
Description: The format of the sessions may include: a greeting song to orient the participant to the start of the session; singing of 1-3 preferred/chosen songs to address cognition and communication; two movement songs with instrument playing interventions to stimulate cognition and movement; songwriting for self-expression, cognitive, and emotional support; relaxation/mindfulness; a closing song to help the participant transition at the completion of the session, The music therapist also provides training to caregivers in techniques to utilize music for behavioral support.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Personalized music CD
Description: Participants will receive a personalized music CD that they keep and can listen to as they wish.
Study: NCT05634473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methacholine Chloride
Description: Cholinergic agonists
Study: NCT04780529

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gucy2c cart cells
Description: Patients with advanced malignant gastrointestinal tumors were injected with CART cells
Study: NCT05065801

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: GABRINOX
Description: Patients in the experimental arm received sequential treatment: 3 cycles of GEMBRAX followed by 2 cycles of FOLFIRINOX

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRINOX
Description: Patients in this arm received reatment: 3 cycles of FOLFIRINOX